Top 10 Holdings of Caligan Partners
Founded in 2017, Caligan Partners is one of the most significant specialty hedge funds.
Enanta Pharmaceuticals Inc (ENTA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Farallon Capital Thomas Steyer | 2,095,000 | $27,172,150 | 0.12% | |
| 2. | Armistice Capital Steven Boyd | 1,096,000 | $14,215,120 | -12% | 0.17% |
| 3. | Marshall Wace LLP Paul Marshall And Ian Wace | 928,363 | $12,040,868 | -3% | 0.01% |
| 4. | Soleus Capital Guy Levy | 799,546 | $10,370,112 | +38% | 0.91% |
| 5. | Millennium Management Israel Englander | 683,143 | $8,860,365 | -4% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $24.45 | 500 | Officer | 1,900 | 2016-05-11 | Filing | |
| $27.04 | 2,000 | Director | 15,295 | 2016-02-12 | Filing | |
| $34.20 | 600 | Director | 2,000 | 2015-02-19 | Filing | |
| $33.69 | 400 | Director | 1,400 | 2015-02-18 | Filing | |
| $33.10 | 400 | Officer | 1,400 | 2015-02-17 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.08 | 5,375 | Officer | 21,717 | 2024-07-15 | Filing | |
| $15.04 | 2,271 | Officer | 21,717 | 2024-07-12 | Filing | |
| $15.07 | 4,299 | Officer | 23,988 | 2024-07-11 | Filing | |
| $12.33 | 7,266 | Officer | 32,341 | 2024-06-17 | Filing | |
| $9.12 | 15,295 | Director | 5,800 | 2023-12-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,934,711 | $18,205,631 | 0% | |
| 2. | 1,793,786 | $16,879,526 | 0% | |
| 3. | 1,173,058 | $11,038,481 | 0% | |
| 4. | 935,493 | $8,802,989 | 0% | |
| 5. | 583,658 | $5,492,222 | 0.01% |
News See All
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2024 Earnings Call Transcript
Operator: Good afternoon and welcome to Enanta Pharmaceuticals' Fiscal Second Quarter Financial Results Conference Call. At this time, all participants are on a listen-only mode.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q1 2024 Earnings Call Transcript
Operator: Good afternoon and welcome to Enanta Pharmaceuticals' Fiscal First Quarter Financial Results Conference Call. At this time, all participants are on a listen-only mode.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q4 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to Enanta Pharmaceuticals Fiscal Fourth Quarter and Year-End Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Top 5 Stock Picks of Farallon Capital
In this article, we discuss the top 5 stock picks of Farallon Capital.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q3 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to Enanta Pharmaceuticals’ Fiscal Third Quarter Financial Results Conference Call. At this time, all participants are in a listen only mode.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q2 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to Enanta Pharmaceuticals Fiscal Second Quarter Ended March 31, 2022 Financial Results Conference Call. At this time, all participants are in a listen only mode.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q1 2023 Earnings Call Transcript
Operator: Good afternoon, and welcome to Enanta Pharmaceuticals Fiscal First Quarter Ended December 31, 2022 Financial Results Conference Call. At this time all participants are in a listen only mode.
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q4 2022 Earnings Call Transcript
Operator: Good afternoon, and welcome to Enanta Pharmaceuticals Fiscal Fourth Quarter and Full Year Ended September 30, 2022 Financial Results Conference Call.
10 Best Pharmaceutical Stocks to Buy According to Steven Boyd's Armistice Capital
In this article, we will take a look at some of the notable pharma stocks to buy according to Steven Boyd's Armistice Capital.